Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • By

  • July 7, 2026

  • 8 min

Share

Objective:

To present new radiation oncology research and clinical expertise at the 2026 ASTRO Annual Meeting.

Approach:
  • Research Areas: The research covers MR-guided adaptive radiation therapy, radiopharmaceutical therapy, proton therapy, stereotactic radiosurgery, and treatment timing for various complex cancers.
  • Clinical Focus: Studies address significant clinical needs in brain metastases, prostate cancer, pancreaticobiliary cancer, colorectal cancer, breast cancer, oropharyngeal cancer, anal cancer, and pediatric and young adult lymphoma.
Key Findings:
  • Analysis of PSMA PET-derived biomarkers in metastatic castration-resistant prostate cancer.
  • Early intracranial radiotherapy improves survival in breast cancer brain metastases.
  • Ablative MR-guided adaptive radiotherapy is effective for anatomically challenging tumors.
  • Outcomes following proton craniospinal irradiation for solid tumor leptomeningeal metastasis.
Interpretation:

Conclusion:

Baptist Health researchers will present multiple oral and poster presentations, contributing to advancements in radiation oncology.

Sources:

Original Source(s)

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

  • by

  • July 7, 2026

Related Content

Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details

Correction: Integrative subtyping by bile acid metabolism identifies CLCA1/UGT2A3/ZG16 as markers of immune dysfunction and poor prognosis in colorectal cancer

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min